The "Siemens Incident" revelation: the rise of national brands was at the time

At the beginning of May, the "Oilong Incident" of "Siemens was investigated" was once a hot topic. The most talked about is that multinational giants have dominated the medical device market in China for many years, resulting in a high price, which has aggravated the problem of “expensive medical treatment”. This incident has once again aroused the attention of all parties on domestic medical devices, and they are eagerly awaiting that national brands can dominate the market.

National brands have received much attention

Talking about the development of China's medical device industry in recent years, it is gratifying that medical devices are the fastest-growing industries in China in recent years; worries are that the industry is small in scale and weak in research and development capabilities, and truly has high-tech products with completely independent intellectual property rights or There are few innovative products with cutting-edge technology.

Due to the low level of innovation in China's medical device industry, the lack of core technologies and the small influence of brands, domestic medical device companies have been “inactive” in the high value-added high-end medical device market.

However, as the country pays more and more attention to medical device technology innovation, this situation is gradually changing. This can be seen from the 73rd China International Medical Devices (Spring) Expo (hereinafter referred to as CMEF) held in Shanghai in May.

From May 15 to 18, CMEF, regarded as the vane of the medical device industry , was held in Shanghai. According to media reports, there are more than 600 new products on the market, including 3D printing, genetic diagnosis and many other cutting-edge technology products. Among many high-tech medical device products with cutting-edge technology, there are many domestic companies.

"There is a significant change in this exhibition. In the field of high-end medical equipment, it is no longer a stage for foreign-invested enterprises. Many domestic excellent enterprises have exhibited many domestic innovative products, attracting many visitors and domestic and foreign merchants." The general manager of a medical device company who participated in the exhibition told reporters.

At CMEF, the national brand Shanghai Lian Ying not only received much attention from the industry, but also one of the outstanding domestic enterprises that participated in the exhibition.

It is understood that Shanghai Lian Ying has displayed all the core technologies from the main research and development and more than 20 high-end medical equipments with completely independent intellectual property rights in CMEF, and competed with foreign giants on the same stage, which has attracted great attention from outside the industry. At the same time, Lian Ying released the "U+ Internet Medical" strategic layout for the first time, mainly launching three industry-first high-end medical imaging products: dynamic multi-pole 3.0T magnetic resonance (MR) instrument, dual-mode 128-layer CT machine, mrCT.

Shanghai Lian Ying R & D personnel introduced that the dynamic multi-pole 3.0T MR launched this time uses the dynamic multi-pole adjustment technology and open source creation platform pioneered by Lian Ying, which can build a cooperation platform for MR research, research, research and medicine for clinical researchers. Helping to break the barriers of scientific research and realize the free sharing of professional scientific research results; the industry's first dual-mode 128-slice CT equipped with China's first self-developed high-end "space-time" detector, creating dual-modal imaging, while scanning speed doubled It can greatly improve the detection rate of small lesions and early lesions; the industry's first mrCT can provide low-density resolution and multi-modal iterative low-dose algorithms for real-time holographic multi-dimensional imaging.

“At this exhibition, national brands are not far behind the multinational giants. Take Shanghai Lian Ying, no matter the position or scale of the booth, and the number of new products released, compared with the multinational medical device giants, there is no disadvantage. Even the looting of the multinational giants. The industry is most pleased that in the high value-added medium and high-end products, foreign brands are no longer the 'protagonists', and many national brands have revealed many new products. It has demonstrated strong innovation capability and good development prospects, and revealed the enthusiasm of foreign companies, which is rare in the past.” A provincial food and drug supervision bureau staff participated in the exhibition. The reporter said.

Saving power to break the high-end market

The reporter noted that in addition to Shanghai Lianyin's launch of a number of innovative products, Shenzhen Mindray and many other well-known medical device companies in China have high-profile announcements on the CMEF to display a large number of innovative products, in the hands of foreign companies that have long monopolized China's high-end medical device market. Get a piece of it.

The reporter learned from the Ministry of Science and Technology that at present, like digital flat panel X-ray machine, 64-row CT, high-end color ultrasound, 1.5T magnetic resonance imaging system, PET-CT, implantable rechargeable bilateral side pacemaker, heart stent, etc. A number of major products have successfully broken the localization of foreign monopoly, and a number of cutting-edge technologies have achieved pioneering breakthroughs. The industrial fields such as medical imaging have shown a trend of accelerating the evolution to the high-end of the value chain. China's medical device technology and industry competition The power has improved significantly.

Among the high-end products that break the monopoly of foreign-funded enterprises, the national brands have made great contributions and demonstrated certain competitiveness. However, in the high-end market, do national brands really have the strength and emboldened power of “selling” multinational giants?

"As far as the level of medical device development in China is concerned, it does not have such strength. Although in recent years, national brands have developed rapidly and have made breakthroughs in certain high-end products, but from the comprehensive strength and the impact of the global medical device market. From the point of view, there is still a long way to go before national brands can compete with multinational giants.” In the “3rd National Medical Device Regulatory Policy Seminar” hosted by the newspaper recently, one The representative of the company told reporters.

Carbomer

Carbomer is an acrylic resin obtained by cross-linking pentaerythritol with acrylic acid. It is a very important rheological regulator. After neutralization, carbomer is an excellent gel matrix, which has important applications such as thickening suspension. According to the dry product calculation, including carboxylic acid group (-cooh) should be 56.0 % ~ 68.0%.

Common carbopol series include: Carbopol 940, 941, 934, 1342, 980, ETD 2020, AQUA sf-1, Ultrez 21, Ultrez 20, etc.

Carbomer,Carbopol,Carbopol 940, Carbomer 940, Carbomer 980, acrylic acid

Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualynbio.com